2020
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.Peer-Reviewed Original ResearchInsulin-naïve patientsInsulin useBackground glucose-lowering therapyEMPA-REG OUTCOMEInsulin dose increasesInsulin-treated patientsGlucose-lowering therapyEmpagliflozin 10T2D durationInsulin doseT2D diagnosisInsulin needsPlaceboPatientsWeight gainKey covariatesDose increaseInsulinTreatment effectsNew initiationHypoglycemiaT2DTherapyYrDiagnosis
2013
Patterns of care and side effects for patients prescribed methadone for treatment of chronic pain.
Macey TA, Weimer MB, Grimaldi EM, Dobscha SK, Morasco BJ. Patterns of care and side effects for patients prescribed methadone for treatment of chronic pain. Journal Of Opioid Management 2013, 9: 325-33. PMID: 24353045, PMCID: PMC4001870, DOI: 10.5055/jom.2013.0175.Peer-Reviewed Original ResearchConceptsChronic painSide effectsSingle VA medical centerInitiation of methadoneInsufficient pain reliefCardiac side effectsChronic pain patientsHealth service utilizationPatterns of careMedical record dataVA Medical CenterNew initiationOpioid initiationPain reliefPain patientsQTc prolongationSustained releaseService utilizationClinical dataClinical significanceMedical CenterCalendar year 2008PatientsClinical information systemsMethadone
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply